HLA-DRB1*04:05 is involved in the development of Vogt–Koyanagi–Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) activate anti-tumor activity by inhibiting immune checkpoint molecules that suppress inflammatory T-cell activity. However, ICIs can initiate excessive immune responses, thereby causing immune-related adverse events (irAEs). ICI-associated uveitis (ICIU) is an irA...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Masaki, Meguro, Akira, Nakamura, Jutaro, Chikagawa, Rei, Osada, Raiga, Shibuya, Etsuko, Hasumi, Yukiko, Yamada, Norihiro, Ishihara, Mami, Mizuki, Nobuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442432/
https://www.ncbi.nlm.nih.gov/pubmed/37604934
http://dx.doi.org/10.1038/s41598-023-40565-z

Ejemplares similares

Ejemplares similares